Clinical Trials Browser

Terminated × Melanoma × 30 days × Clear all

Brain Neoplasms, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Melanoma, Neoplasm Metastasis, Hematologic Neoplasms, Triple Negative Breast Neoplasms

NCT06799533 2026-03-18

A Study to Learn About the Study Medicine Called PF-08046031 in Advanced Melanoma and Other Solid Tumors

Phase 1 Terminated

11 enrolled

Dermatologic

Melanoma

NCT00421317 2026-03-13

O-Mel-Inib

Phase 2 Terminated

13 enrolled

Dermatologic

Melanoma

NCT04221438 2026-03-12

Testing Treatment With Encorafenib and Binimetinib Before Surgery for Melanoma With Lymph Node Involvement

Phase 2 Terminated

3 enrolled 11 charts

Dermatologic

Lymphatic Metastasis, Melanoma

NCT05926960 2026-03-09

PORTSIDE

Phase 2 Terminated

38 enrolled

Dermatologic

Melanoma, Skin Neoplasms

NCT06287463 2026-03-05

Study of DCC-3084 in Participants With Advanced Malignancies Driven by the Mitogen-Activated Protein Kinase (MAPK) Pathway

Phase 1 Terminated

29 enrolled

DermatologicThoracic

Carcinoma, Non-Small-Cell Lung, Melanoma

NCT03420963 2026-03-03

Donor Natural Killer Cells, Cyclophosphamide, and Etoposide in Treating Children and Young Adults With Relapsed or Refractory Solid Tumors

Phase 1 Terminated

12 enrolled

DermatologicGenitourinaryHead & NeckOther solid neoplasmSarcomaThoracic

Mesothelioma, Malignant, Bone Neoplasms, Endocrine Gland Neoplasms, Melanoma, Mouth Neoplasms, Pharyngeal Neoplasms, Sarcoma, Skin Neoplasms, Thyroid Neoplasms, Urologic Neoplasms

NCT03716193 2026-02-27

Measurement of the Partial Pressure of Oxygen in Cutaneous Tumors Using Electron Paramagnetic Resonance (EPR) Oximetry

Phase NA Terminated

3 enrolled

Dermatologic

Melanoma, Skin Neoplasms

NCT04093323 2026-02-25

Polarized Dendritic Cell (aDC1) Based Treatment, Interferon Alpha-2, Rintatolimod, and Celecoxib for the Treatment of HLA-A2+ Refractory Melanoma

Phase 2 Terminated

1 enrolled

Dermatologic

Melanoma

NCT03428581 2026-02-24

Preventing Lymphedema in Axillary Lymph Node Dissection

Phase NA Terminated

264 enrolled

BreastDermatologic

Breast Neoplasms, Lymphedema, Melanoma

NCT06587451 2026-02-24

Integrated Pharmacokinetics (PK)/Efficacy, Safety, and Immunogenicity Study to Demonstrate Similarity of JPB898, a Proposed Biosimilar to Nivolumab, to Opdivo® in Combination With Yervoy®

Phase 3 Terminated

52 enrolled

Dermatologic

Melanoma

NCT06546553 2026-02-23

A Study to Learn About How Different Amounts of the Study Medicine PF-07826390 Act in the Body of People With Cancer When Taken Alone or With Other Anti-cancer Medicines.

Phase 1 Terminated

10 enrolled

DermatologicGastrointestinalGenitourinaryGynecologicHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Kidney Neoplasms, Melanoma, Neoplasm Metastasis, Neoplasms, Ovarian Neoplasms, Rectal Diseases, Colorectal Neoplasms

Clinical Trials

Bintrafusp Alfa and Pimasertib for the Treatment of Patients With Brain Metastases

A Study to Learn About the Study Medicine Called PF-08046031 in Advanced Melanoma and Other Solid Tumors

O-Mel-Inib

Testing Treatment With Encorafenib and Binimetinib Before Surgery for Melanoma With Lymph Node Involvement

PORTSIDE

Study of DCC-3084 in Participants With Advanced Malignancies Driven by the Mitogen-Activated Protein Kinase (MAPK) Pathway

Donor Natural Killer Cells, Cyclophosphamide, and Etoposide in Treating Children and Young Adults With Relapsed or Refractory Solid Tumors

Measurement of the Partial Pressure of Oxygen in Cutaneous Tumors Using Electron Paramagnetic Resonance (EPR) Oximetry

Polarized Dendritic Cell (aDC1) Based Treatment, Interferon Alpha-2, Rintatolimod, and Celecoxib for the Treatment of HLA-A2+ Refractory Melanoma

Preventing Lymphedema in Axillary Lymph Node Dissection

Integrated Pharmacokinetics (PK)/Efficacy, Safety, and Immunogenicity Study to Demonstrate Similarity of JPB898, a Proposed Biosimilar to Nivolumab, to Opdivo® in Combination With Yervoy®

A Study to Learn About How Different Amounts of the Study Medicine PF-07826390 Act in the Body of People With Cancer When Taken Alone or With Other Anti-cancer Medicines.